Sienna slumps as acne asset flunks phase 3 trials

Sienna slumps as acne asset flunks phase 3 trials

Source: 
Fierce Biotech
snippet: 

Sienna Biopharmaceuticals’ acne candidate SNA-001 has comprehensively failed two phase 3 trials. The addition of the silver particle treatment to laser light therapy failed to improve outcomes against three key endpoints, leaving the future of Sienna’s most advanced candidate in doubt.